GB201006753D0 - Process for preparing an immunolobulin composition - Google Patents

Process for preparing an immunolobulin composition

Info

Publication number
GB201006753D0
GB201006753D0 GBGB1006753.6A GB201006753A GB201006753D0 GB 201006753 D0 GB201006753 D0 GB 201006753D0 GB 201006753 A GB201006753 A GB 201006753A GB 201006753 D0 GB201006753 D0 GB 201006753D0
Authority
GB
United Kingdom
Prior art keywords
immunolobulin
preparing
composition
immunolobulin composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1006753.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest AG
Original Assignee
Biotest AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42270688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201006753(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotest AG filed Critical Biotest AG
Priority to GBGB1006753.6A priority Critical patent/GB201006753D0/en
Publication of GB201006753D0 publication Critical patent/GB201006753D0/en
Priority to HK13105491.8A priority patent/HK1177600B/en
Priority to KR1020127030528A priority patent/KR101860459B1/ko
Priority to PCT/EP2011/056487 priority patent/WO2011131787A2/en
Priority to PCT/EP2011/056486 priority patent/WO2011131786A2/en
Priority to SG2012076063A priority patent/SG184844A1/en
Priority to MX2012012263A priority patent/MX338195B/es
Priority to HUE11715567A priority patent/HUE025853T2/en
Priority to CA2796409A priority patent/CA2796409A1/en
Priority to RU2012149741A priority patent/RU2617532C2/ru
Priority to EP11715928.5A priority patent/EP2560691B1/en
Priority to CN201611045494.0A priority patent/CN107080842A/zh
Priority to PL11715567.1T priority patent/PL2560682T5/pl
Priority to KR1020127030527A priority patent/KR101872747B1/ko
Priority to BR112012026934-8A priority patent/BR112012026934B1/pt
Priority to RU2017111820A priority patent/RU2749732C2/ru
Priority to AU2011244241A priority patent/AU2011244241B2/en
Priority to AU2011244240A priority patent/AU2011244240B2/en
Priority to CN201180029337.XA priority patent/CN102939107B/zh
Priority to ES11715567T priority patent/ES2551605T5/es
Priority to SG2012076055A priority patent/SG184843A1/en
Priority to RU2016140455A priority patent/RU2765738C2/ru
Priority to CA2796263A priority patent/CA2796263C/en
Priority to BR112012026937-2A priority patent/BR112012026937B1/pt
Priority to RU2012149743A priority patent/RU2612899C2/ru
Priority to MX2012012262A priority patent/MX337060B/es
Priority to EP11715567.1A priority patent/EP2560682B2/en
Priority to CN201180029338.4A priority patent/CN102939111B/zh
Priority to ES11715928.5T priority patent/ES2553385T3/es
Priority to PL11715928T priority patent/PL2560691T3/pl
Priority to HK13107957.1A priority patent/HK1180601B/en
Priority to JP2013511592A priority patent/JP6283517B2/ja
Priority to HUE11715928A priority patent/HUE028581T2/en
Priority to JP2013511591A priority patent/JP6118248B2/ja
Priority to IL222373A priority patent/IL222373A/en
Priority to IL222374A priority patent/IL222374A/en
Priority to US13/655,686 priority patent/US8900806B2/en
Priority to US13/655,649 priority patent/US9243056B2/en
Priority to ZA2012/08541A priority patent/ZA201208541B/en
Priority to ZA2012/08540A priority patent/ZA201208540B/en
Priority to CO12211856A priority patent/CO6640239A2/es
Priority to CO12211854A priority patent/CO6640238A2/es
Priority to US14/529,400 priority patent/US9518110B2/en
Priority to JP2016110121A priority patent/JP6612182B2/ja
Priority to JP2016118887A priority patent/JP6612186B2/ja
Priority to US15/348,121 priority patent/US10059759B2/en
Priority to US16/029,781 priority patent/US10954290B2/en
Priority to US17/168,848 priority patent/US11780909B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1006753.6A 2010-04-22 2010-04-22 Process for preparing an immunolobulin composition Ceased GB201006753D0 (en)

Priority Applications (48)

Application Number Priority Date Filing Date Title
GBGB1006753.6A GB201006753D0 (en) 2010-04-22 2010-04-22 Process for preparing an immunolobulin composition
HK13105491.8A HK1177600B (en) 2010-04-22 2011-04-21 Process for preparing an immunoglobulin composition
KR1020127030528A KR101860459B1 (ko) 2010-04-22 2011-04-21 항체 조제물
PCT/EP2011/056487 WO2011131787A2 (en) 2010-04-22 2011-04-21 Antibody preparations
PCT/EP2011/056486 WO2011131786A2 (en) 2010-04-22 2011-04-21 Process for preparing an immunoglobulin composition
SG2012076063A SG184844A1 (en) 2010-04-22 2011-04-21 Antibody preparations
MX2012012263A MX338195B (es) 2010-04-22 2011-04-21 Preparaciones de anticuerpos.
HUE11715567A HUE025853T2 (en) 2010-04-22 2011-04-21 Antibody Compositions
CA2796409A CA2796409A1 (en) 2010-04-22 2011-04-21 Process for preparing an immunoglobulin composition
RU2012149741A RU2617532C2 (ru) 2010-04-22 2011-04-21 Препараты антител
EP11715928.5A EP2560691B1 (en) 2010-04-22 2011-04-21 Process for preparing an immunoglobulin composition
CN201611045494.0A CN107080842A (zh) 2010-04-22 2011-04-21 抗体制剂
PL11715567.1T PL2560682T5 (pl) 2010-04-22 2011-04-21 Preparaty przeciwciałowe
KR1020127030527A KR101872747B1 (ko) 2010-04-22 2011-04-21 면역글로불린 조성물의 제조 방법
BR112012026934-8A BR112012026934B1 (pt) 2010-04-22 2011-04-21 PROCESSO PARA A PREPARAÇÃO DE UMA COMPOSIÇÃO DE IMUNOGLOBULINA CONTENDO IgM, PREPARAÇÃO DE ANTICORPO, E USO DE UMA PREPARAÇÃO DE ANTICORPO
RU2017111820A RU2749732C2 (ru) 2010-04-22 2011-04-21 Препараты антител
AU2011244241A AU2011244241B2 (en) 2010-04-22 2011-04-21 Antibody preparations
AU2011244240A AU2011244240B2 (en) 2010-04-22 2011-04-21 Process for preparing an immunoglobulin composition
CN201180029337.XA CN102939107B (zh) 2010-04-22 2011-04-21 抗体制剂
ES11715567T ES2551605T5 (es) 2010-04-22 2011-04-21 Preparaciones de anticuerpos
SG2012076055A SG184843A1 (en) 2010-04-22 2011-04-21 Process for preparing an immunoglobulin composition
RU2016140455A RU2765738C2 (ru) 2010-04-22 2011-04-21 Способ получения композиции иммуноглобулинов
CA2796263A CA2796263C (en) 2010-04-22 2011-04-21 Igm antibody preparations
BR112012026937-2A BR112012026937B1 (pt) 2010-04-22 2011-04-21 Preparação de anticorpo apropriada para administração intravenosa em humanos, e, uso da mesma
RU2012149743A RU2612899C2 (ru) 2010-04-22 2011-04-21 Способ получения композиции иммуноглобулинов
MX2012012262A MX337060B (es) 2010-04-22 2011-04-21 Proceso para preparar una composicion de inmunoglobulina.
EP11715567.1A EP2560682B2 (en) 2010-04-22 2011-04-21 Antibody preparations
CN201180029338.4A CN102939111B (zh) 2010-04-22 2011-04-21 制备免疫球蛋白组合物的方法
ES11715928.5T ES2553385T3 (es) 2010-04-22 2011-04-21 Proceso para preparar una composición de inmunoglobulina
PL11715928T PL2560691T3 (pl) 2010-04-22 2011-04-21 Sposób wytwarzania kompozycji immunolobulinowej
HK13107957.1A HK1180601B (en) 2010-04-22 2011-04-21 Antibody preparations
JP2013511592A JP6283517B2 (ja) 2010-04-22 2011-04-21 抗体調製物
HUE11715928A HUE028581T2 (en) 2010-04-22 2011-04-21 A method for preparing an immunoglobulin preparation
JP2013511591A JP6118248B2 (ja) 2010-04-22 2011-04-21 免疫グロブリン組成物を調製するためのプロセス
IL222373A IL222373A (en) 2010-04-22 2012-10-11 Process for making an immunoglobulin preparation
IL222374A IL222374A (en) 2010-04-22 2012-10-11 Antiviral cleanser
US13/655,686 US8900806B2 (en) 2010-04-22 2012-10-19 Antibody preparations
US13/655,649 US9243056B2 (en) 2010-04-22 2012-10-19 Process for preparing an immunoglobulin composition
ZA2012/08541A ZA201208541B (en) 2010-04-22 2012-11-13 Antibody preparations
ZA2012/08540A ZA201208540B (en) 2010-04-22 2012-11-13 Process for preparing an immunoglobulin composition
CO12211856A CO6640239A2 (es) 2010-04-22 2012-11-22 Proceso par preparar una composición de inmunoglobulina
CO12211854A CO6640238A2 (es) 2010-04-22 2012-11-22 Preparaciones de anticuerpos
US14/529,400 US9518110B2 (en) 2010-04-22 2014-10-31 Antibody preparations
JP2016110121A JP6612182B2 (ja) 2010-04-22 2016-06-01 免疫グロブリン組成物を調製するためのプロセス
JP2016118887A JP6612186B2 (ja) 2010-04-22 2016-06-15 抗体調製物
US15/348,121 US10059759B2 (en) 2010-04-22 2016-11-10 Antibody preparations
US16/029,781 US10954290B2 (en) 2010-04-22 2018-07-09 IgG, IgA and IgM antibody preparations, method of making and method of use in treatment
US17/168,848 US11780909B2 (en) 2010-04-22 2021-02-05 Methods of treating viral infections by administering an antibody preparation comprising IGG, IGA and IGM

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1006753.6A GB201006753D0 (en) 2010-04-22 2010-04-22 Process for preparing an immunolobulin composition

Publications (1)

Publication Number Publication Date
GB201006753D0 true GB201006753D0 (en) 2010-06-09

Family

ID=42270688

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1006753.6A Ceased GB201006753D0 (en) 2010-04-22 2010-04-22 Process for preparing an immunolobulin composition

Country Status (18)

Country Link
US (6) US9243056B2 (enExample)
EP (2) EP2560691B1 (enExample)
JP (4) JP6283517B2 (enExample)
KR (2) KR101872747B1 (enExample)
CN (3) CN107080842A (enExample)
AU (2) AU2011244241B2 (enExample)
CA (2) CA2796409A1 (enExample)
CO (2) CO6640239A2 (enExample)
ES (2) ES2553385T3 (enExample)
GB (1) GB201006753D0 (enExample)
HU (2) HUE028581T2 (enExample)
IL (2) IL222374A (enExample)
MX (2) MX337060B (enExample)
PL (2) PL2560682T5 (enExample)
RU (4) RU2765738C2 (enExample)
SG (2) SG184844A1 (enExample)
WO (2) WO2011131786A2 (enExample)
ZA (2) ZA201208541B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
FR2959821B1 (fr) * 2010-05-05 2012-07-06 Lab Francais Du Fractionnement Procede de mesure de l'activation du complement par des igg
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
KR102142261B1 (ko) 2012-03-09 2020-08-11 체에스엘 베링 아게 분비형 면역글로불린을 포함하는 조성물
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
KR20150115639A (ko) * 2014-04-04 2015-10-14 전숙영 치료용 면역글로불린 제제 제조에 사용되는 산성 완충액, 이를 이용한 치료용 면역글로불린 제제 제조방법 및 이 제조방법으로 제조된 치료용 면역글로불린 제제
WO2016011054A2 (en) * 2014-07-15 2016-01-21 The Regents Of The University Of California Novel treatment for polycystic kidney disease
EP3334747B1 (en) 2015-08-13 2023-09-27 Amgen Inc. Charged depth filtration of antigen-binding proteins
ES2881201T3 (es) 2016-03-14 2021-11-29 Biotest Ag Tratamiento de la neumonía grave adquirida en la comunidad
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
RU2660584C1 (ru) * 2017-06-06 2018-07-06 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ определения FC-функции препаратов иммуноглобулина человека
PL3717916T3 (pl) * 2017-11-29 2025-04-07 F. Hoffmann-La Roche Ag Test do oznaczania przeciwciał przeciwlekowych z tłumieniem oddziaływania z cząsteczką docelową
EP3747903A1 (en) 2019-06-07 2020-12-09 Biotest AG Method and kit for testing potency of immunoglobulin compositions
CN115697395A (zh) * 2020-04-10 2023-02-03 瓦努迪斯有限公司 预防和治疗中的天然抗体
CN115697408A (zh) * 2020-06-03 2023-02-03 基立福环球运营有限公司 超免疫igg和/或igm组合物及其制备方法及自捐献者获得超免疫人血浆的方法
TW202216735A (zh) * 2020-07-10 2022-05-01 愛爾蘭商格里佛全球營運有限公司 製備包含人血漿來源的免疫球蛋白ｍ之組合物的方法及儲存穩定的液體組合物
CN111944043B (zh) * 2020-09-01 2023-05-09 华兰生物工程重庆有限公司 一种从血浆废弃物中提取IgM的方法
EP4193155A1 (en) 2020-11-19 2023-06-14 Biotest AG Method and kit for testing immunomodulatory potency of immunoglobulin compositions, e.g., for treatment of covid-19
EP4377361A1 (en) 2021-07-29 2024-06-05 CSL Behring AG Method of purifying immunoglobulin g and uses thereof
WO2024200757A1 (en) 2023-03-29 2024-10-03 Csl Behring Ag Methods of identifying immunoglobulin associated with adverse reactions
WO2025008781A1 (en) 2023-07-04 2025-01-09 Csl Behring Ag Method of purification
WO2025229607A1 (en) 2024-05-03 2025-11-06 Csl Behring Ag Systems and methods for solid-liquid separation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US136556A (en) 1873-03-04 Improvements in button-fastenings
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
US4371520A (en) * 1981-10-28 1983-02-01 The Green Cross Corporation Process for preparing immunoglobulin suitable for intravenous injection
DE3310150A1 (de) * 1983-03-21 1984-09-27 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation
IL90281A (en) 1988-06-06 1994-10-07 Miles Inc Preparations containing MGI antibodies
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US4939176A (en) 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
DE3927112C1 (enExample) 1989-08-17 1990-10-25 Biotest Pharma Gmbh, 6072 Dreieich, De
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US5367054A (en) * 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
DE29624488U1 (de) 1995-07-14 2004-04-15 Croix-Rouge De Belgique Anlage zur Inaktivierung von in Blutprodukten enthaltenen Kontaminierungen
EP0764658B1 (de) 1995-09-22 2002-01-02 ZLB Bioplasma AG Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
EP0835880A1 (de) * 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
JP3987599B2 (ja) * 1996-12-05 2007-10-10 日本製薬株式会社 筋ジストロフィー治療剤
JPH10167894A (ja) * 1996-12-11 1998-06-23 Mitsubishi Gas Chem Co Inc ビスマス置換希土類鉄ガーネット単結晶膜の製造法
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
PL196770B1 (pl) 1998-06-09 2008-01-31 Statens Seruminstitut Sposób oczyszczania immunoglobuliny, produkt immunoglobuliny i jego zastosowanie
RU2178309C2 (ru) * 2000-01-12 2002-01-20 Российский научно-исследовательский институт геронтологии Антитимоцитарный глобулин для внутривенного введения и способ его получения
RU2192279C2 (ru) * 2000-09-07 2002-11-10 Нижегородское государственное предприятие по производству бактерийных препаратов Способ получения иммуноглобулинового препарата
AU2002229545B2 (en) 2000-11-13 2007-08-30 Bayer Aktiengesellschaft Method of inactivating microorganisms in a fluid using ultraviolet radiation
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003037504A1 (en) 2001-11-02 2003-05-08 Japan Techno Co., Ltd. Vibratory stirrer for sterilization and sterilizer and sterilization method employing vibratory stirrer
RU2255766C2 (ru) * 2003-03-05 2005-07-10 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габрического Министерства здравоохранения Российской Федерации" Способ получения иммуноглобулинового препарата для профилактики и терапии бактериальных и вирусных инфекций, иммуноглобулиновый препарат для профилактики и терапии бактериальных и вирусных инфекций (варианты) и суппозитории на основе иммуноглобулинового препарата
US8980646B2 (en) 2003-03-26 2015-03-17 Sudhir Paul Proteolytic and covalent antibodies
AU2004286938B2 (en) 2003-10-27 2011-06-30 Wyeth Removal of high molecular weight aggregates using hydroxyapatite chromatography
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
EP1709077A1 (en) 2004-01-30 2006-10-11 Suomen Punainen Risti Veripalvelu Process for the manufacture of virus safe immunoglobulin
PL1718675T3 (pl) 2004-02-27 2013-09-30 Octapharma Ag Sposób uzyskiwania oczyszczonego preparatu przeciwciał pozbawionego wirusów
ES2348792T3 (es) 2004-12-10 2010-12-14 Novimmune Sa TERAPIAS COMBINADAS DIRIGIDAS A MÚLTIPLES RECEPTORES TIPO TOLL Y USO DE LAS MISMAS.
WO2006064373A2 (en) 2004-12-16 2006-06-22 Genzyme Polyclonals S.A.S. Methods of purifying immunologlobulins
KR101157174B1 (ko) 2005-11-24 2012-06-20 삼성전자주식회사 세포 또는 바이러스의 신속한 파괴 방법 및 장치
DE102005062634A1 (de) 2005-12-23 2007-06-28 Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH Verfahren zur Inaktivierung von Pathogenen in Spenderblut, Blutplasma oder Erythrozytenkonzentraten in flexiblen Behältnissen unter Bewegung
FR2899112B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament.
FR2899111B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
US8354076B2 (en) 2006-10-02 2013-01-15 Palo Alto Research Center Incorporated Fluid stirring mechanism
EP1950225A1 (de) 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
AU2009246510B2 (en) 2008-05-12 2014-02-13 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
RU2457863C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов
RU2457861C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
NZ591514A (en) 2011-03-03 2013-11-29 Kode Biotech Ltd Assay method

Also Published As

Publication number Publication date
MX338195B (es) 2016-04-06
AU2011244240B2 (en) 2014-12-04
KR101872747B1 (ko) 2018-06-29
BR112012026934A2 (pt) 2015-09-22
IL222374A0 (en) 2012-12-31
IL222374A (en) 2017-04-30
WO2011131786A2 (en) 2011-10-27
KR20130094718A (ko) 2013-08-26
ES2551605T5 (es) 2024-06-27
ES2551605T3 (es) 2015-11-20
AU2011244241B2 (en) 2014-12-04
RU2016140455A3 (enExample) 2020-04-02
JP6612186B2 (ja) 2019-11-27
ZA201208541B (en) 2015-06-24
CA2796263A1 (en) 2011-10-27
PL2560682T3 (pl) 2016-04-29
RU2016140455A (ru) 2018-12-17
US20150064170A1 (en) 2015-03-05
US10954290B2 (en) 2021-03-23
RU2012149741A (ru) 2014-05-27
BR112012026937A2 (pt) 2016-07-12
RU2749732C2 (ru) 2021-06-16
JP2016222674A (ja) 2016-12-28
US20170058020A1 (en) 2017-03-02
MX2012012262A (es) 2012-11-23
WO2011131787A3 (en) 2011-12-22
JP2016196477A (ja) 2016-11-24
US8900806B2 (en) 2014-12-02
US9518110B2 (en) 2016-12-13
IL222373A (en) 2016-02-29
KR101860459B1 (ko) 2018-05-23
PL2560691T3 (pl) 2016-04-29
CO6640238A2 (es) 2013-03-22
HK1180601A1 (zh) 2013-10-25
US20180319871A1 (en) 2018-11-08
CO6640239A2 (es) 2013-03-22
CN102939111B (zh) 2014-10-29
CN107080842A (zh) 2017-08-22
SG184843A1 (en) 2012-11-29
PL2560682T5 (pl) 2024-04-29
EP2560682B1 (en) 2015-10-21
IL222373A0 (en) 2012-12-31
HK1177600A1 (zh) 2013-08-23
EP2560682B2 (en) 2024-01-17
CA2796409A1 (en) 2011-10-27
US20210179694A1 (en) 2021-06-17
EP2560691B1 (en) 2015-11-04
JP6612182B2 (ja) 2019-11-27
JP2013531630A (ja) 2013-08-08
EP2560682A2 (en) 2013-02-27
AU2011244240A1 (en) 2012-12-06
JP6283517B2 (ja) 2018-02-21
CA2796263C (en) 2019-05-14
RU2017111820A (ru) 2019-01-24
US20130045199A1 (en) 2013-02-21
RU2012149743A (ru) 2014-05-27
CN102939107A (zh) 2013-02-20
MX2012012263A (es) 2012-11-23
US20130052208A1 (en) 2013-02-28
MX337060B (es) 2016-02-09
KR20130060199A (ko) 2013-06-07
WO2011131786A3 (en) 2011-12-22
ES2553385T3 (es) 2015-12-09
AU2011244241A1 (en) 2012-12-06
US9243056B2 (en) 2016-01-26
US10059759B2 (en) 2018-08-28
CN102939111A (zh) 2013-02-20
RU2617532C2 (ru) 2017-04-25
JP2013530950A (ja) 2013-08-01
RU2017111820A3 (enExample) 2020-07-20
HUE028581T2 (en) 2016-12-28
CN102939107B (zh) 2016-12-21
ZA201208540B (en) 2015-06-24
RU2765738C2 (ru) 2022-02-02
SG184844A1 (en) 2012-11-29
WO2011131787A2 (en) 2011-10-27
RU2612899C2 (ru) 2017-03-13
EP2560691A2 (en) 2013-02-27
HUE025853T2 (en) 2016-05-30
US11780909B2 (en) 2023-10-10
JP6118248B2 (ja) 2017-04-19

Similar Documents

Publication Publication Date Title
GB201006753D0 (en) Process for preparing an immunolobulin composition
GB201011502D0 (en) Novel process
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
IL225510A0 (en) Processes for preparing improved preparations
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
HU1000010D0 (en) Novel process
IL222290A0 (en) Process for preparing aminobenzofuran derivatives
EP2534127A4 (en) PROCESS FOR PREPARING (R) 2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE
IL222191A0 (en) Process for preparing sulfonamido-benzofuran derivatives
GB201009673D0 (en) Novel process
HU1000386D0 (en) Novel process
GB201009676D0 (en) Novel process
ZA201207386B (en) Process for preparing benzoxaboroles
GB201009671D0 (en) Novel process
IL227872A0 (en) A process for the preparation of n-converted phenylhydroxylamines
IL218140A0 (en) Process for preparing 1-phenylpyrazoles
IL227220A (en) A process for preparing a history of 3-alkylsulfinylbenzoyl
ZA201206099B (en) Process for preparing an alkene
GB201004301D0 (en) Process
ZA201207291B (en) Process for preparing silicon-containing azodicarbamides
EP2619174A4 (en) PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES
LT2571902T (lt) Naujas būdas
GB201004299D0 (en) Process
IL223145A0 (en) Process for preparing dithiine-tetracarboxy-diimides
IL224619A (en) A process for the preparation of cyclo-lignans

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)